Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. SEC filings (Ticker: SCNI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scinai Immunotherapeutics Ltd. filings document foreign private issuer reporting for a Nasdaq-listed ADS issuer operating biopharmaceutical R&D and CDMO businesses. Form 6-K reports furnish current information on material agreements, clinical and regulatory disclosures for PC111 and related immunology programs, Nasdaq minimum bid price notices, capital-structure matters, and incorporation of current reports into Form F-3 and Form S-8 registration statements.
The filing record also documents the completed acquisition of Recipharm Israel Ltd., renamed Scinai Biopharma Services Ltd., including audited subsidiary financial statements and unaudited pro forma consolidated and combined financial information. Proxy and governance filings cover annual general meeting materials, ADS voting procedures, board composition changes, auditor selection, risk factors, and shareholder voting matters.
Scinai Immunotherapeutics Ltd. submitted a Form 6-K providing a business update for the first half of 2025. The filing includes a press release, condensed interim unaudited financial statements, and an operating and financial review and prospects, each as of June 30, 2025.
The company also states that this Form 6-K, including these exhibits, is incorporated by reference into its existing registration statements on Form S-8 and Form F-3. This links the new interim information directly into Scinai’s previously filed securities registration documents.